Kite, A Gilead Company, Presents Long-Term Data For Yescarta CAR T-Cell Therapy At ASH 2023 That Demonstrate High Rate Of Durable Response In Patients With High-Risk Large B-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Kite, a subsidiary of Gilead Sciences, presented long-term data at ASH 2023 showing that its Yescarta CAR T-cell therapy has a high rate of durable response in patients with high-risk large B-cell lymphoma. This data could positively impact Gilead's reputation in the oncology market and potentially its stock price.
December 11, 2023 | 10:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive long-term data for Yescarta presented by Kite could enhance Gilead Sciences' position in the oncology market, potentially leading to increased sales and a positive impact on GILD's stock price in the short term.
The presentation of successful long-term data for a key product like Yescarta is likely to be viewed positively by investors and could lead to increased investor confidence in Gilead's growth within the oncology sector. This could result in a short-term uptick in GILD's stock price as the market reacts to the potential for increased future revenues from Yescarta.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90